To follow or contribute to the discussion around news breaking from ASCO, click here to access Doximity's Newsfeed. Thank you and we hope you enjoy the conference!
Read below for a recap of ASCO Day #3 highlights by Dr. Chandler Park, Doximity's Hematology/Oncology Ambassador. Dr. Park kicked off Day #3 with an interview of Dr. Karim Fizazi.
Today we have an interview with the the lead author of the LATITUDE Trial. The most popular 2017 ASCO plenary session. Dr. Karim Fizazi is an oncologist at the University of Paris-Sud.
Dr. Chandler Park: Dr. Fizazi, phenomenal results on the LATITUDE Trial. This study is practice changing for all medical oncologists around the world. Thank you for taking the time to talk to our Doximity audience that cannot be at ASCO this year.
Dr. Karim Fizazi: Very glad to help.
Dr. Chandler Park: Dr. Fizazi with the outstanding results of this study. Would you consider Androgen Deprivation therapy with Abiraterone plus prednisone for all newly diagnosed high-risk metastatic hormone naïve prostate cancers? I’m interested in your thoughts with patients with cardiovascular morbidities since one of the main side effects are an increase in cardiovascular risk factors .
Dr. Karim Fizazi: You are right. We need to be cautious. Some patients cannot tolerate this combo. Not everyone can tolerate abiaterone, prednisone, and medical castation. When we are running trials we are excluding high risk patients . We need to remember that. We are still doctors and we need to know these drugs and know our patients.
Dr. Chandler Park: So which patients would you be cautious giving this regimen?
Dr. Karim Fizazi: Obese gentleman with severe diabetes and recent cardiovascular disease. At the very least refer to cardiologists and diabetes doctor to fix the problem the best before starting this treatment. Fix that problem.
Dr. Chandler Park; So what do you consider “high risk” patients?
Dr. Karim Fizaz: LATITUDE paper considers high risk patients with 2 or 3 out of 3 risk factors. These 3 risk factors are Gleason Score 8 or higher, 3 or more bone lesions, and measurable visceral metastatic disease.
Dr. Park: We have had outstanding practice changing advances in prostate cancer the last couple years with the CHAARTED, STAMPEDE, and now with the LATITUDE trial. What study should we keep an eye on in the next couple years.
Dr. Karim Fizazi: In Europe we are currently investigating Androgen Deprivation Therapy, Docetaxel plus or minus Abiaterone with Prednisone. We will eventually know whether Abiaterone with Prednisone in a backbone of ADT and Docetaxel demonstrates superior activity. Perhaps in 2-3 years, this study will mature.
Dr. Chandler Park: Dr. Fizazi thank you very much for your time.